Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

(2009) S. P. Hilchey et al.   BLOOD

CD20-targeted tetrameric interferon- , a novel and potent immunocytokine for the therapy of B-cell lymphomas

(2009) E. A. Rossi et al.   BLOOD

Intratumoral But Not Systemic Delivery of CpG Oligodeoxynucleotide Augments the Efficacy of Anti-CD20 Monoclonal Antibody Therapy Against B Cell Lymphoma

(2009) David J. Betting et al.   JOURNAL OF IMMUNOTHERAPY

Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas

(2009) T. Olafsen et al.   JOURNAL OF NUCLEAR MEDICINE

Inhibitors of MyD88-Dependent Proinflammatory Cytokine Production Identified Utilizing a Novel RNA Interference Screening Approach

(2009) John S. Cho et al.   PLoS One

Tumor-Targeted Interferon-α Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis

(2008) Michele De Palma et al.   CANCER CELL

Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study

(2008) Guillaume Cartron et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group

(2008) Eva Kimby et al.   LEUKEMIA & LYMPHOMA